We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Siemens Healthineers

Provides customized electronic systems and advanced imaging, diagnostics, therapy, and healthcare IT solutions for th... read more Featured Products: More products

Download Mobile App





Siemens SARS-CoV-2 Total Antibody Test Granted FDA Emergency Use Authorization

By LabMedica International staff writers
Posted on 23 Jun 2021
Print article
Image: The Siemens Healthineers SARS-CoV-2 Total (COV2T) Assay (Photo courtesy of Siemens Healthineers)
Image: The Siemens Healthineers SARS-CoV-2 Total (COV2T) Assay (Photo courtesy of Siemens Healthineers)
Siemens Healthineers (Erlangen, Germany) has been issued an Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for its laboratory-based total antibody test to detect the presence of SARS-CoV-2 antibodies, including IgM and IgG in blood.

Test data demonstrated 100% sensitivity and 99.8% specificity. Siemens’ Total Antibody COV2T assay allows for identification of patients who have developed an adaptive immune response, which indicates recent infection or prior exposure. Testing can begin immediately with more than one million tests already shipped to health systems and laboratories. A spike protein on the surface of the SARS-CoV-2 virus enables the virus to penetrate and infect human cells found in multiple organs and blood vessels. Siemens’ Total Antibody COV2T assay was thoughtfully designed to detect antibodies to the spike protein. These antibodies are believed to neutralize the SARS-CoV-2 virus and therefore prevent infection. Multiple potential vaccines in development for SARS-CoV-2 include the spike protein within their focus.

The total antibody test SARS-CoV-2 Total (COV2T) is available on the largest installed base of high-throughput analyzers, including the Atellica IM immunoassay analyzers, which can run up to 440 tests per hour and enables a result in just 10 minutes. The test also is available on the company’s expansive installed base of ADVIA Centaur XP and XPT analyzers, which can test up to 240 samples per hour with a result in 18 minutes.

“As a leader in laboratory diagnostics, Siemens Healthineers designed a high-quality, highly accurate antibody test with the capacity and reach necessary to help address a critical societal need,” said Deepak Nath, PhD, President, Laboratory Diagnostics, Siemens Healthineers. “The test targets both IgM and IgG antibodies, which allows for early identification of individuals infected with the virus who have developed an immune response, even if they were asymptomatic or never diagnosed with the disease.”

“As one of the leading specialized laboratories, we recognized the critical need of our customers to have rapid and accurate testing to manage COVID-19 among their patients and staff," said Paul F. Beyer, CEO of Ascend Clinical. “The Siemens Healthineers total antibody test enables us to confidently deliver fast, reliable results that will be extremely valuable in the surveillance of the disease.”

Related Links:
Siemens Healthineers

Gold Supplier
Sample Transport
VACUETTE Transport Line
New
Neonatal Analyzer
CareStart S1 Analyzer
New
Silver Supplier
SARS-CoV-2 Antigen Test
NG-Test SARS-NG-Test SARS-CoV-2 Ag Cassette
New
Laboratory Management Software
HERA

Print article

Channels

Pathology

view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more

Industry

view channel
Illustration

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.